Andrew Cherico, a student at the University of Central Florida, Orlando, FL, discusses his experience living with spinal muscular atrophy (SMA), the impacts of available treatments, and how the condition intersects with his passion for sports journalism. He is joined by John W. Day, MD, PhD, Professor of Neurology and Pediatrics, Director, Division of Neuromuscular Medicine at Stanford University School of Medicine, and Co-Director of Stanford’s Neuro IGNITE Center, Stanford, CA, who describes the importance of genetic testing, the landscape of available SMA treatments, and the significance of the newly approved one-time gene therapy Itvisma (onasemnogene abeparvovec-brve; Novartis, East Hanover, NJ).